constructed a T lymphocyte depletion (TLP) mouse model and found that the anti-tumor effect of PD-1 therapy was severely impaired in TLP mice, depending on the degree of TLP and the immunogenicity of the tumor. Here, PDCD1 is linked to neoplasm.